On the other hand, demecarium, a cholinesterase inhibitor used for topical treatment of glaucoma, is a representative example of a drug without temporal continuity—demecarium was first suggested as an AD repurposing candidate in 2014 (Croset et al., 2014), with subsequent support in two studies (Jamal et al., 2015; Zhang et al., 2016); however, after 2016, the drug was not mentioned again. This evidence concerns the gene BCHE and glaucoma.